Login to Your Account



On-‘DEMAND’ data: Sarepta, Prosensa return DMD optimism

By Jennifer Boggs
Managing Editor

Friday, January 17, 2014
SAN FRANCISCO – After clinical and regulatory setbacks in the latter part of 2013, the news might be getting better for patients with Duchenne’s muscular dystrophy (DMD), as two of the most advanced programs reported news at the J.P. Morgan Healthcare Conference.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription